RxDoctor Payments Data

Raul Reyes, MD

Family Medicine · Harlingen, TXNPI 1942560594

Payments from drug & device makers

$522in general payments, 2019–2025

Across 17 payments — averaging $30.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$389
  • Novo Nordisk$34
  • Phadia US Inc.$25
  • Abbott$21
  • Pfizer$19
  • Dexcom, Inc.$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC10$389
Novo Nordisk2$34
Phadia US Inc.1$25
Abbott1$21
Pfizer1$19
Dexcom, Inc.1$17
AstraZeneca1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$133,046
Medicare patients
335
Services billed
1,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$56,367
JardianceEmpagliflozin24$33,423
Tresiba Flextouch U-200Insulin Degludec17$22,679
EliquisApixaban21$22,135
MounjaroTirzepatide19$20,162
JanuviaSitagliptin Phosphate13$18,172
FarxigaDapagliflozin Propanediol22$17,934
XareltoRivaroxaban11$15,482
JanumetSitagliptin Phos/Metformin Hcl20$11,046
Tresiba Flextouch U-100Insulin Degludec13$8,143
Breo ElliptaFluticasone/Vilanterol15$7,131
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,951
Lisinopril186$1,464
Atorvastatin Calcium217$1,441
Albuterol Sulfate HfaAlbuterol Sulfate57$1,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$56,36755 claims
PfizerEliquis$19$22,13521 claims
Lilly USA, LLCMounjaro$389$20,16219 claims
AstraZenecaFarxiga$17$17,93422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →